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Abstract Continuous renal replacement therapy (CRRT)
is commonly used for renal support in the intensive care
unit. While the risk of medication errors in the intensive
care unit has been described, errors related specifically to
CRRT are unknown. The purpose of this study is to
characterize medication errors related to CRRT and
compare medication errors that occur with manually
compounded solutions versus commercially available
solutions. We surveyed three separate internet-based,
pediatric list serves that are commonly used for commu-
nications for programs utilizing CRRT. Data regarding
CRRT practices and medication errors were recorded.
Medication errors were graded for degree of severity and
compared between programs using manually compounded
dialysis solutions versus commercially available dialysis
solutions. In a survey with 31 program responses, 18
reported medication errors. Two of the 18 were related to
heparin compounding, while 16/18 were due to solution
compounding errors. Half of the medication errors were
classified as causing harm, two of which were fatal. All
medication errors were reported by programs that manually
compounded their dialysis solutions. Medication errors
related to CRRT are associated with a high degree of
severity, including death. Industry-based, commercially
available solutions can decrease the occurrence of medi-
cation errors due to CRRT.
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Introduction
Continuous renal replacement therapy (CRRT) was first
introduced in 1977 for fluid overload in the intensive care
unit and has now become commonplace in the critical care
setting [1, 2]. CRRT encompasses a variety of techniques
with clearance mechanisms that utilize a convective mode
[(continuous veno-venous hemofiltration (CVVH)], a
diffusive mode [(continuous veno-venous hemofiltration
with dialysis (CVVHD)] or a combination [(continuous
veno-venous hemodiafiltration (CVVHDF)] [3]. All CRRT
modalities require either replacement solutions (for con-
vection) or dialysis solutions (for diffusion) [4]. Typically,
these solutions have been bicarbonate based, as data have
shown that bicarbonate-based solutions improve hemody-
namic stability and outcome in patients compared to
lactate-based solutions [5]. Prior to 2000, however, no
Food and Drug Administration (FDA)-approved bicarbon-
ate solutions were available in the United States of
America; therefore, many programs began using pharmacy
made solutions that were compounded manually.
There is considerable risk for medication errors when a
high volume of dialysis solutions are compounded
manually. For example, a single patient may require up
to 50 l of dialysis solutions per day. This leads to a
substantial increase in workload on behalf of the pharmacy,
with the average time to prepare one 3 l bag being
approximately 20–30 min. Since these solutions are not
routinely assayed and verified for the proper concentration,
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many errors go unrecognized. Programs have privately
reported medication errors related to dialysis solutions for
CRRT, yet published data, until recently, have been non-
existent [6].
Currently, there are three industry-developed, bicarbon-
ate-based solutions that are FDA approved: Normocarb
(Dialysis Solutions, Richmond Hills, Ontario, Canada),
Prismasate (Gambro, Lakewood, Calif., USA) and Accusol
(Baxter, Deerfield, Ill., USA). It is presumed that these
standardized, pre-mixed solutions will offer a tremendous
advantage with regard to medication safety.
The purpose of this study is to characterize medication
errors related to dialysis solutions used for CRRT.
Secondly, medication errors will be compared between
pharmacy-made/manually compounded solutions and in-
dustry-based/commercially available solutions.
Materials and methods
Internet-based list serves were used to capture data related
to medication errors and CRRT. Three individual list serves
were queried, which included pediatric critical care [i.e.,
PedsCCM (http://pedsccm.wustl.edu/PedsCCM_Home_
page.html)], pediatric nephrology [i.e., PEDNEPH (http://
listhost.uchicago.edu/mailman/listinfo/pedneph)] and pe-
diatric CRRT [i.e., PEDCRRT (http://listhost.uchicago.
edu/mailman/listinfo/pedcrrt)]. Those list serves are made
up of over 1,000 clinicians and allow for communication
among programs, both publicly and privately, as well as
open discussion between critical care physicians, nephrol-
ogists, nurses, and pharmacists. Overall, there are approxi-
mately 100 to 120 individual programs within the members
of these list serves. Information requested included the
CRRT modality used (convective vs diffusive clearance),
the type of anticoagulation (heparin vs citrate), the type of
solutions used (manually compounded vs commercially
available), as well as complications related to any of the
above. In addition, programs were asked if they did
identify errors, what steps were taken to correct the
problems. All respondents were asked to return comments
privately and assured that all communication would be
destroyed and that the data would be tabulated without
there being any ability to link back to the primary source.
The principle investigator of this study (T.E.B.) reviewed
all data and ensured that there were no duplications within
programs.
The severity of medication errors was categorized by
criteria developed by the National Coordinating Council
for Medication Error Reporting and Prevention [7]. This
system uses three major categories of errors (i.e., no harm,
harm, death), with various subcategories under each
division (Table 1).
Descriptive statistics were used, as most data were not
amenable to inferential testing. To compare medication
errors between manually compounded and industry-based
dialysis solutions we used, as appropriate, either Pearson’s
chi square test or Fisher’s exact test. A P value <0.05 was
considered statistically significant. SPSS, version 13.0
(Chicago, Ill., USA) was used for all analyses.
Results
Thirty-one programs responded to the question. Patient
volumes of CRRT per year ranged from two to 41.
Modalities included CVVH (nine programs), CVVHD
(seven programs), CVVHDF (seven programs), and
varying CRRT modalities (eight programs). The anticoag-
ulant used was heparin in 20 programs and citrate in 11
programs. Of the 20 programs that used diffusive methods,
13 utilized manually compounded, bicarbonate-based
solutions, while seven programs utilized commercially
available, industry-based solutions (bicarbonate-based
Normocarb in two programs, bicarbonate-based Prismasate
in two programs, and lactate-based Baxter hemofiltration
solution in three programs). Of the 20 programs that used
convective clearance methods, 14 utilized manually
compounded, bicarbonate-based solutions, two utilized
industry-developed, bicarbonate-based (Normocarb) and
four utilized normal saline or lactate Ringer’s solutions.
Of the 31 programs, 18 (58%) noted at least one error.
Table 2 lists the errors categorized according to severity.
Two errors involved anticoagulation, and 16 were due to
solution compounding errors. In those programs that had
anticoagulation errors, both were related to improper
mixing of heparin solutions, resulting in over-hepariniza-
tion of the patients. Both of these resulted in non-life
threatening, mild bleeding. The remaining 16 errors
involved compounding errors, all of which were reported
by programs using manually compounded solutions:
seven used for replacement and nine used for dialysate.
There were no errors reported by programs using industry-
made solutions (Table 3). The patient complications
associated with these errors included six seizures related
to either hypo- or hypernatremia, one cardiac arrest (with






Category B Error, but medication did not reach patient
Category C Error reaches patient, but no harm
Error reaches patient, but not administered
Category D Error occurred, resulted in increased patient
monitoring, but no harm to patient
Error,
harm
Category E Resulted in need for therapy or intervention,
caused temporary harm
Category F Resulted in initial or prolonged hospital-
ization and temporary harm to patient
Category G Resulted in permanent harm





survival) and two fatalities. Both fatalities were related to
inappropriate potassium concentrations, while the cardiac
arrest was related to calcium. Seven patients had no
complications.
Programs that reported errors implemented changes in
order to avoid future risk. Of those reviewed, 13 programs
changed from pharmacy-made, manually compounded,
bicarbonate-based solutions to commercially available,
industry-developed, bicarbonate-based solutions for either
replacement or dialysate solution (11 Normocarb, and two
Prismasate). Two programs purchased automated solution
compounders to be used specifically for large-volume
parenteral solutions, ten programs began having nursing
staff double check the labels of all bags, and many
programs implemented pre-printed orders to minimize
handwriting legibility errors. Three programs initiated the
practice of confirming the composition of each solution by
laboratory analysis. Interestingly, programs that utilized
chemical analysis of each dialysate or replacement solution
reported a delay of up to 45 min for delivery of the solution
to the bedside, compared to the previous time that solutions
were available.
Discussion
Medication dosing and drug preparation in pediatrics
requires multiple considerations and thus can be time
consuming and error prone [8–11]. Despite the high
recognition of medication safety, the prevention of med-
ication errors continues to be a major undertaking for
clinicians in healthcare today. While various methods exist
to detect medication errors, it is difficult to quantify and/or
catch errors related to dialysis solutions, since most are
related to compounding/mixing the solution itself. Since
few institutions chemically test solutions for the proper
additives, many errors go unrecognized. In fact, only a
single report exists describing a compounding error that
resulted in excessive potassium in CRRT solutions,
ultimately leading to the deaths of two patients [6]. Reports
of medication errors in pediatric CRRT have been
discussed at national meetings but have never been
quantified. This lack of quantification has not been helpful
in supporting the need for industry-made solutions for
CRRT.
Recent reports have described the incidence of medica-
tion errors in the intensive care unit (ICU). In one study of
error-prone medications, the percentage of errors classified
as “causing harm” was 1% [12]. The drug classes
associated with the most errors were vasoactive medica-
tions (33%) followed by sedative/analgesics (26%). In a
second study, 11% of serious errors were considered life
threatening [13]. Most errors (61%) occurred during the
ordering or execution of treatment. We noted that half of
the reported errors specific to CRRTwould be classified as
causing harm. Furthermore, over half of the respondents of
this survey have reported medication errors related to
CRRT solutions. Although it is difficult to comment on the
true incidence of medication errors related to CRRT, when
they do occur, they can be associated with significant
adverse clinical outcomes.
A majority of the medication errors reported were related
to compounding or mixing the dialysis solutions. Most
institutions still compound their dialysis solutions by
manually adding each individual electrolyte, despite there
being a number of industry-based solutions commercially
available. In 2000, Normocarb was the first bicarbonate-
based solution made available for CRRT. This is now being
used for dialysis as well as replacement fluid [5, 14, 15]. In
2002, Gambro introduced their product, Prismasate, which
is available for dialysate. Finally, in 2004, Baxter devel-
oped their bicarbonate-based solution, Accusol.
The availability of these industry-made solutions offers
tremendous advantages in terms of efficiency and patient
safety. It is pertinent that clinicians recognize their
availability. The economic impact of these solutions has
not been determined, but factors that must be considered
are the cost and time devoted to preparation, along with the
cost of a medication error. While the acquisition cost of
these solutions may be higher than the cost of the
constituents used to manually compound dialysis solutions,
the overall cost to the system may be lower when the
consequences of an error are included. We encourage
programs that are using extemporaneously made solutions
to consider the use of commercially available solutions to
minimize serious and potentially lethal complications
associated with solution compounding in CRRT.
While most medication errors were related to dialysis
solutions, two involved anticoagulation. Anticoagulation
protocols for CRRT are either heparin based or citrate
based. Medication errors with heparin are common in the
ICU and may, in part, be due to the varying concentrations
in which it can be prepared. Citrate is available in pre-
mixed bags as either trisodium citrate or anticoagulant
citrate dextrose solution formula A (ACD-A) [5, 14–16].
The concentrations of citrate and sodium are different in the
two solutions and, at first glance, may appear similar. The
Table 2 Severity of medication errors
Major division Subcategory Number of errors (%)
Error, no harm Category C 7 (39%)
Category D 2 (11%)
Error, harm Category F 6 (33%)
Category H 1 (6%)
Error, death Category I 2 (11%)
Total errors 18
Table 3 Medication errors and solution type
Solution Number of errors P
Manually Compounded Industry Developed
Dialysate 9/13 0/7 0.005
Replacement 7/14 0/6 0.051
Total 16/27 0/13 <0.001
The data are reported as number of errors/number of programs
similar appearance allows for the potential of a substitution
error or a sound-alike/look-alike error. Institutions are
encouraged to implement safeguards to prevent this from
occurring or, ideally, to have only one product available on
formulary.
Limitations of our study include the inability to report a
true incidence of medication errors related to CRRT, due to
the manner in which programs were queried. Regardless of
the incidence, however, clinicians must recognize that
serious medication errors can occur with CRRT . Secondly,
medication errors could have occurred that were not
clinically significant and therefore not recognized. Finally,
the number of institutions that did respond to this query
may not be representative of the entire CRRT community.
Conclusion
In conclusion, medication errors related to CRRT solutions
are associated with a high degree of severity, including
death. The available industry-made bicarbonate-based
solutions are safe and are a reasonable alternative to
manually compounded solutions. These commercially
available solutions facilitate efficient patient care, mark-
edly reduce the risk of compounding error, and may reduce
the liability for the institution.
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